Cáncer de Próstata | 合法醫療器材資訊網
TheSiemensportfolioofPSAassaysprovidesyourhealthcareclientswithmore...Quantitativelymeasuresprostatespecificantigeninserum;Classicscreening ...
1. NACB Laboratory Medicine Practice Guidelines. Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast and Ovarian Cancers. 2009. 2. The IMMULITE Third Generation PSA assay has not been evaluated and approved by the FDA for use with the IMMULITE Free PSA assay in the percent free PSA calculations. 3. Shen, et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J of Urol 2005; 173; 777-780. 4. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7. ...
Cáncer de Próstata | 合法醫療器材資訊網
Class 2 Device Recall IMMULITEIMMULITE 2000 PSA Assay | 合法醫療器材資訊網
IMMULITE | 合法醫療器材資訊網
IMMULITE and IMMULITE 1000 System | 合法醫療器材資訊網
Missing agreement between the two IMMULITE® PSA assays | 合法醫療器材資訊網
New developments in the standardization of total prostate ... | 合法醫療器材資訊網
P930027S004c.pdf | 合法醫療器材資訊網
Premarket Approval (PMA) | 合法醫療器材資訊網
Prostate Cancer | 合法醫療器材資訊網
Ultrasensitive detection of prostate | 合法醫療器材資訊網
【免疫特前列腺異性抗原試劑】許可證字號:衛署醫器輸字第013472號
器材品名:免疫特前列腺異性抗原試劑許可證字號:衛署醫器輸字第013472號註銷狀態:註銷日期:註銷理由:有效日期:2025/11/03發證...